

Abstract

The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAP α), said prodrug is chemically stable under physiological conditions and can be used for the manufacture of physically stable aqueous formulations. It has a cleavage site which is recognised by FAP α , and the drug released by the enzymatic activity of FAP α is cytotoxic or cytostatic under physiological conditions.